Revvity (NYSE:RVTY) Given New $115.00 Price Target at Evercore ISI

Revvity (NYSE:RVTY - Get Free Report) had its price target decreased by research analysts at Evercore ISI from $116.00 to $115.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Evercore ISI's target price would suggest a potential upside of 15.50% from the stock's previous close.

Several other equities research analysts have also issued reports on the stock. Barclays decreased their price target on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Wall Street Zen upgraded Revvity from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Robert W. Baird dropped their price target on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research report on Tuesday, April 29th. Bank of America dropped their target price on shares of Revvity from $116.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, UBS Group upgraded shares of Revvity from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Revvity currently has a consensus rating of "Moderate Buy" and a consensus target price of $123.07.

Revvity Stock Up 0.9%

NYSE:RVTY opened at $99.57 on Tuesday. The firm has a market capitalization of $11.74 billion, a price-to-earnings ratio of 42.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.98. The stock's 50 day moving average price is $94.12 and its two-hundred day moving average price is $104.73. Revvity has a twelve month low of $87.70 and a twelve month high of $129.50. The company has a quick ratio of 2.99, a current ratio of 3.58 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a net margin of 10.35% and a return on equity of 7.73%. The firm had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same quarter in the prior year, the business posted $0.98 EPS. The business's revenue was up 2.3% compared to the same quarter last year. Equities research analysts expect that Revvity will post 4.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revvity

A number of institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp grew its position in Revvity by 39.8% in the 4th quarter. Jones Financial Companies Lllp now owns 4,312 shares of the company's stock worth $481,000 after purchasing an additional 1,228 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Revvity by 17.4% in the 4th quarter. Victory Capital Management Inc. now owns 70,250 shares of the company's stock worth $7,841,000 after buying an additional 10,390 shares in the last quarter. Assetmark Inc. grew its holdings in Revvity by 3,700.0% in the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after buying an additional 259 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in Revvity by 12,298.3% in the 4th quarter. Proficio Capital Partners LLC now owns 195,769 shares of the company's stock worth $21,850,000 after buying an additional 194,190 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Revvity during the fourth quarter valued at $2,248,000. Institutional investors own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.